PartnershipApr 23, 2026, 07:32 AM
Plus Therapeutics initiates manufacturing with SpectronRx for REYOBIQ
AI Summary
Plus Therapeutics announced the initiation of manufacturing activities and technology transfer with SpectronRx under a Master Services Agreement. This establishes SpectronRx as a second GMP manufacturing site for Rhenium-186 and REYOBIQ, alongside Radiomedix, strengthening the company's multi-partner supply chain. The move aims to bolster manufacturing readiness and expand production capacity for REYOBIQ's late-stage clinical supply needs, with a target completion by 2026.
Key Highlights
- Initiated manufacturing and technology transfer with SpectronRx.
- SpectronRx becomes second GMP manufacturing site for REYOBIQ.
- Aims to complete manufacturing scale-up for REYOBIQ by 2026.
- Strengthens multi-partner supply chain for Rhenium-186 and REYOBIQ.